1. M10 Persistence on antifibrotic medication in idiopathic pulmonary fibrosis (IPF) is not dependent on distance travelled to tertiary centre. (12th November 2019) Authors: Babu, A; McLellan, T; Verghese, P; Harris, E; Harding, K; Simler, N; Fiddler, C; Parfrey, H; Woodhead, F; Thillai, M Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. M15 Antifibrotic medications for idiopathic pulmonary fibrosis (IPF): a real world single centre experience of 447 patients over a 6 year period. (12th November 2019) Authors: Harris, E; Harding, K; McLellan, T; Babu, A; Verghese, P; Parfrey, H; Simler, N; Fiddler, C; Thillai, M Journal: Thorax Issue: Volume 74(2019)Supplement 2 Page Start: A243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P106 Addition of pulmonary rehabilitation does not appear to improve six-minute walk or pulmonary function in patients with idiopathic pulmonary fibrosis treated with anti-fibrotic medications. (December 2018) Authors: Francis, CE; Sylvester, KP; Chiu, Y; Thillai, M Journal: Thorax Issue: Volume 73(2018)Supplement 4 Page Start: A159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P155 Use of mycophenolate mofetil and azathioprine in patients with chronic hypersensitivity pneumonitis. (15th November 2017) Authors: Fiddler, CA; Simler, N; Thillai, M; Parfrey, H Journal: Thorax Issue: Volume 72(2017)Supplement 3 Page Start: A167 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗